Peptide Therapy & Longevity Protocol Platform
Telemedicine platform connecting patients with physicians specializing in peptide therapy and longevity protocols — BPC-157, GHK-Cu, thymosin, and more — with lab monitoring, dosing optimization, and outcomes tracking.
Problem Solved
Peptide therapy demand surging but finding knowledgeable physicians is difficult. Peptide quality and sourcing is unregulated and dangerous. No standardized protocols or outcomes tracking exists. Patients self-administering without medical oversight risk adverse effects.
Target Audience
Longevity enthusiasts, biohackers, athletes seeking recovery, anti-aging medicine patients, functional medicine practitioners
Revenue Model
$199-$499 initial consultation. Follow-ups at $99-$199. Pharmacy partnership revenue. Revenue target: $200K-$1.5M ARR by year 2.
Key Features to Build
- Physician matching for peptide therapy
- Lab-monitored protocol management
- AI dosing optimization
- Outcomes tracking and reporting
- Pharmaceutical-grade sourcing verification
Known Competitors
Why Now — Market Timing
Peptide therapy research accelerating. FDA attention creating need for medical oversight. Biohacking community growing rapidly. Compounding pharmacy industry adapting. Longevity medicine becoming recognized specialty.
Validate This Idea with AI
Get a detailed viability report with market analysis, competition assessment, and financial projections — in minutes.
Validate "Peptide Therapy & Longevity Protocol Platform"